It’s Going Tibia Okay: Supportive Bone Health in Oncology

<p>Christopher R. Cahoon, PharmD defines the importance of optimizing bone health in patients with bone metastases and lytic lesions, describes preferred bone-targeted therapy for patients with malignancy-associated bone disease and discusses the safety limitations associated with bisphosphonates and RANKL inhibitors.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>